News



06/30/2020 - Tissue Regeneration Therapeutics receives Certificate of Patent for Canadian Patent Application No. 2871219 “Immune Privileged and Modulatory Progenitor Cells”.

06/19/2020 - Tissue Regeneration Therapeutics receives Notice of Allowance for Canadian Patent Application No. 2721870 “Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents”.

02/23/2020 - Tissue Regeneration Therapeutics’ Founding President and CEO, Dr. J.E. Davies speaks at the inaugural, virtual, meeting of the Future Investment Initiative (FII) Institute https://youtu.be/x2UejcTkUfE

01/15/2020 - Tissue Regeneration Therapeutics’ collaborator the Scottish National Blood Transfusion Services (SNBTS) together with both the University of Edinburgh and the University of Glasgow, publish a major new paper showing Human Umbilical Cord Perivascular Cells improve human pancreatic islet transplant function. “The immunosuppressive and proregenerative properties of HUCPVCs demonstrated long-term positive effects on graft function in vivo, indicating that they may improve long-term human islet allotransplantation outcomes.” Science Translational Medicine 12: eaan5907 (2020)

01/14/2020 - Tissue Regeneration Therapeutics agrees to grant the Scottish National Blood Transfusion Services (SNBTS) an exclusive license, subject to SNBTS securing the requisite funding, to use Human Umbilical Cord Perivascular Cells as an adjunct to the transplantation of pancreatic islets in the United Kingdom.

10/18/2019 - Tissue Regeneration Therapeutics’ Founding President and CEO, Dr. J.E. Davies speaks at the inaugural meeting of the ON Foundation https://www.on-foundation.org see video

12/10/2018 Press Release - Tissue Regeneration Therapeutics and RoosterBio Inc. Form Strategic Alliance to Commercialize Umbilical Cord Tissue Cell Technology
Read More...

4/6/2017 Press Release - TRT Receives Latest Notice of Patent Grant from the United States Patent Office.
Read More...

8/15/2016 Press Release - TRT engineered mesenchymal stromal cells advance monoclonal antibody therapy.
Read More...

2/16/2016 Press Release - TRT Grants Excusive License for Perivascular Umbilical Cord Stromal/Stem Cell Technology for Family Banking.
Read More...

1/3/2016 Press Release - TRT receives notice of latest patent grant from the State of Israel Patent Office.
Read More...

9/25/2015 Press Release - TRT grants exclusive Canadian license for its patent: Viable Cells From Frozen Umbilical Cord Tissue, for Family Banking.
Read More...

3/24/2015 Press Release - TRT receives notice of latest patent grant from the Korean Intellectual Property Office.
Read More...

3/30/2015 Press Release - TRT receives latest notice of Patent Grant from the United States Patent Office.
Read More...

10/17/2014 Press Release - TRT reaches final milestone of a $3.25 Million funding.
Read More...

6/20/2014 Press Release - TRT Cell-Based Bioweapon Defense Technology Presented at the International Society for Stem Cell Research Conference.
Read More...

6/2/2014 Press Release - Tissue Regeneration Therapeutics Inc. (TRT) and Héma-Québec enter a definitive licensing agreement for the first human clinical trial of TXP-1.
Read More...

7/10/2013 Press Release - Tissue Regeneration Therapeutics Inc. (TRT) raises $3.25 Million to accelerate the development of its Mesenchymal Cell therapeutics platform
Read More...

11/13/2012 University of Toronto - TRT's HUCPVCs Outperform Bone Marrow Cells in Repairing Damaged Hearts
Read More...

11/12/2012 OGI - Ontario Genomics Institute Invests in Stem Cell Technology at Tissue Regeneration Therapeutics
Read More...

10/28/2011 PRESS RELEASE - Tissue Regeneration Therapeutics Grants Exclusive U.S. License for PeriVascular Umbilical Cord Stem Cell Technology to PerkinElmer's ViaCord© Cord Blood Banking Business.
Read More...

6/14/2011 PRESS RELEASE - Trendsetters: Canadian Company Leads Stem Cell Industry in Research and Development
Read More...